Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma : why clinical trials might have failed and how they could succeed

Meemanage, MadushaSpender, Lindsay CCollinson, DianeIannetta, JoannaChallapalli, PranaviTurbitt, JulieClark, CarolineBaxter, MarkMurray, GraemeWalsh, ShaunMiedzybrodzka, ZofiaPetty, Russell D2021-03-092021-03-092021-03-01Meemanage, M, Spender, L C, Collinson, D, Iannetta, J, Challapalli, P, Turbitt, J, Clark, C, Baxter, M, Murray, G, Walsh, S, Miedzybrodzka, Z & Petty, R D 2021, 'Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma : why clinical trials might have failed and how they could succeed', Cancer Chemotherapy and Pharmacology, vol. 87, pp. 361–377. https://doi.org/10.1007/s00280-020-04187-w0344-5704ORCID: 0000-0003-2055-4572ORCID: /0000-0003-2890-8136/work/175113392https://hdl.handle.net/2164/16002Acknowledgements We thank Alice Savage for technical laboratory assistance. Funding The work undertaken was funded by Ninewells Cancer Campaign (Dundee) and Scottish Government Chief Scientist Office (Grant reference TCS/19/18).171684384engSDG 3 - Good Health and Well-beingChemotherapy combinationsDocetaxelEGFRESCCGastroesophageal cancerGefitinibPlatinumGEFITINIBMULTICENTERPROGNOSTIC VALUECANCERPHASE-III TRIALGROWTH-FACTOR RECEPTOROVEREXPRESSIONAMPLIFICATIONTYROSINE KINASE INHIBITORGENE COPY NUMBERR MedicinePharmacology (medical)OncologyCancer ResearchToxicologyPharmacologyOtherRInteractions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma : why clinical trials might have failed and how they could succeedJournal article10.1007/s00280-020-04187-whttp://www.scopus.com/inward/record.url?scp=85095711255&partnerID=8YFLogxK87